Japan's day, wrapped and delivered by morning.
Latest Tokyo Brief coverage on Otsuka Holdings Co., Ltd., tracking filings, financial news, and market signals from Japan.
TSE:4578
An independent panel has unblinded a 285-patient global trial after Otsuka subsidiary Taiho's lung cancer drug beat chemotherapy alone on progression-free survival, opening the door to a first-line approval bid for a mutation with few existing treatments.
Two-year Phase 3 data show sibeprenlimab slows IgA nephropathy patients' kidney decline to roughly the rate seen in healthy aging, a result Otsuka Holdings is using to push VOYXACT toward full US approval.
A slower-than-expected arrival of generic rivals for two of its drugs, plus a weaker yen, is pushing Otsuka Holdings' first-half net profit to ¥215bn, 68% above the guidance it issued in February.
Positive phase 3 data move the IgA nephropathy treatment beyond its earlier proteinuria-based accelerated approval, while leaving Otsuka's outlook for the year ending December 2026 unchanged.